NCT04435314

Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19

Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day for Post Exposure Prophylaxis of COVID-19 in Subjects From Vulnerable Communities

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Azidus Brasil · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 600 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in subjects from vulnerable communities that had direct contact with patients diagnosed with the disease.

Detailed description

The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 600 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in subjects from vulnerable communities that had direct contact with patients diagnosed with the disease. Subjects that PCR is negative after having direct contact with symptomatic subjects and diagnosed with COVID-19 (PCR positive) will be randomized to receive Nitazoxanide TID or placebo TID for 7 days.

Conditions

• covid19

Interventions

Type	Name	Description
DRUG	Nitazoxanide	Subjects will receive nitazonanide 600 mg TID for 7 days
DRUG	Placebo	Subjects will receive placebo TID for 7 days.

Timeline

• Start date: 2020-06-01
• Primary completion: 2020-08-01
• Completion: 2020-08-01
• First posted: 2020-06-17
• Last updated: 2022-10-28